GSK Expands Treasury Stock with Latest Share Buyback

GlaxoSmithKline ( (GB:GSK) ) has issued an update.

GSK plc disclosed that it repurchased 445,000 of its ordinary shares on 13 March 2026 via BNP Paribas at a volume‑weighted average price of 2,041.70 pence, with the shares to be held in treasury as part of its ongoing share buyback programme. Since the programme’s launch on 17 February 2026, GSK has bought back 9,925,409 shares, lifting treasury holdings to 249,816,503 shares, representing 6.14% of voting rights and leaving 4,066,354,262 voting shares in issue, a move that can enhance capital efficiency and potentially support earnings per share for investors.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GSK Stock

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharmaceutical company focused on developing, manufacturing and marketing vaccines, specialty medicines and general pharmaceuticals. The group targets major therapeutic areas such as infectious diseases, respiratory conditions and immunology, serving healthcare systems and patients worldwide through both prescription products and vaccines.

Average Trading Volume: 8,919,089

Technical Sentiment Signal: Buy

Current Market Cap: £81.32B

See more insights into GSK stock on TipRanks’ Stock Analysis page.